Immunome (IMNM)

• Market cap: $1.4B
• 1 day: 0.56%
• 5 days: 0.63%
• 1 month: 37.23%
• 3 months: 52.76%
• 6 months: 82.82%
• Year to date: 52.61%
• 1 year: 40.1%
• 5 years: 46.36%
• 10 years: 19.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Employees: 155